Combating resistance while maintaining innovation: The future of antimicrobial stewardship

Despite the global health threat of antimicrobial resistance, currently the commercial model for antibiotic development does not offer a return on investment, leading to a lack of interest from pharmaceutical companies and very few candidates in the clinical pipeline.

In this perspective piece for Future Microbiology the authors argue that, in addition to a lack of investment, there is a lack of innovation to meet the current shortcomings of antibiotic R&D, discussing the role stewardship could play in revitalizing innovation, the need to move away from a budget-dominated view of antibiotic use, and the increasing interdisciplinary nature of antimicrobial control programs.

Read the full piece

You might also like:

• A peek behind the paper – Sidharth Chopra on drug repurposing to tackle antimicrobial resistance
• First new oral and IV antibiotic with novel mechanism of action approved in nearly two decades